Filtered By:
Specialty: Cardiology
Condition: Obesity
This page shows you your search results in order of date. This is page number 7.
Order by Relevance | Date
Total 639 results found since Jan 2013.
Safety and efficacy of apixaban, dabigatran and rivaroxaban in obese and morbidly obese patients with heart failure and atrial fibrillation: A real ‐world analysis
ConclusionIn obese patients with congestive heart failure and atrial fibrillation or atrial flutter on DOACs, apixaban has the most favorable safety profile compared to rivaroxaban and dabigatran.
Source: Pacing and Clinical Electrophysiology : PACE - December 2, 2022 Category: Cardiology Authors: Yashasvi Chugh,
Kashvi Gupta,
Hanumanthu Balram Krishna,
Renato Quispe Ayala,
Ignacio Zepeda,
Michael Grushko,
Robert T Faillace Tags: ORIGINAL ARTICLE Source Type: research
Safety and Efficacy of Rivaroxaban, Apixaban, and Dabigatran in Obese and Morbidly Obese Patients with Heart Failure and Atrial Fibrillation: A Real ‐World Analysis
ConclusionIn obese patients with congestive heart failure and atrial fibrillation or atrial flutter on DOACs, apixaban has the most favorable safety profile compared to rivaroxaban and dabigatran.This article is protected by copyright. All rights reserved
Source: Pacing and Clinical Electrophysiology : PACE - November 24, 2022 Category: Cardiology Authors: Yashasvi Chugh,
Kashvi Gupta,
Hanumanthu Balram Krishna,
Renato Quispe Ayala,
Ignacio Zepeda,
Michael Grushko,
Robert T Faillace Tags: ORIGINAL ARTICLE Source Type: research
Transitioning to GLP-1 RAs and SGLT2 Inhibitors as the First Choice for Managing Cardiometabolic Risk in Type 2 Diabetes
Abstract Purpose of ReviewThis forward-looking review summarizes existing evidence from cardiovascular outcome trials on cardiometabolic risk-reduction in type 2 diabetes (T2DM) management, with attention to updating and personalizing recommendations from recent diabetes practice guidelines issued by cardiology societies.Recent FindingsT2DM management has shifted towards cardiometabolic outcome improvement rather than purely glycemic control. According to large clinical trials, sodium-glucose cotransporter-2 inhibitors showed robust results in reducing heart failure (HF) hospitalization and chronic kidney disease (CKD) p...
Source: Current Atherosclerosis Reports - November 24, 2022 Category: Cardiology Source Type: research
Association of Epicardial and Pericardial Adipose Tissue Volumes with Coronary Artery Calcification
Int Heart J. 2022 Nov 12. doi: 10.1536/ihj.22-006. Online ahead of print.ABSTRACTEpicardial adipose tissue (EAT) and pericardial adipose tissue (PAT) are anatomically close to the myocardium and may influence cardiovascular pathology. Thus, in this study, we aim to assess whether EAT and PAT volumes were associated with coronary artery calcification score (CCS) in patients with suspected coronary artery disease (CAD), especially in overweight and obese individuals.We included consecutive patients with suspected CAD in whom EAT volume, PAT volume, and CCS were measured via computed tomography between September 2015 and June...
Source: International Heart Journal - November 13, 2022 Category: Cardiology Authors: Jingyi Liu Wenjun Fan Yixiang Liu Haiwei Bu Jian Song Lixian Sun Source Type: research
